• LAST PRICE
    10.4600
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-0.1908%)
  • Bid / Lots
    10.4600/ 24
  • Ask / Lots
    10.4700/ 38
  • Open / Previous Close
    10.4800 / 10.4800
  • Day Range
    Low 10.3300
    High 10.4800
  • 52 Week Range
    Low 8.2450
    High 13.2400
  • Volume
    1,671,571
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 10.48
TimeVolumeROIV
09:32 ET5299010.41
09:34 ET811210.425
09:36 ET368310.42
09:38 ET1472710.42
09:39 ET905010.38
09:41 ET1281310.365
09:43 ET2833510.42
09:45 ET1920810.44
09:48 ET1084910.41
09:50 ET6071610.44
09:52 ET1046910.43
09:54 ET15445010.43
09:56 ET1007010.38
09:57 ET599910.395
09:59 ET1037910.37
10:01 ET987910.34
10:03 ET1206810.34
10:06 ET942810.355
10:08 ET1467410.375
10:10 ET1561010.38
10:12 ET1270010.37
10:14 ET696010.39
10:15 ET1180310.36
10:17 ET700110.365
10:19 ET1030910.35
10:21 ET850410.365
10:24 ET1772910.36
10:26 ET5240010.38
10:28 ET1928510.3925
10:30 ET1508610.38
10:32 ET1712510.38
10:33 ET615310.385
10:35 ET1912410.375
10:37 ET2331410.365
10:39 ET1170910.365
10:42 ET877510.365
10:44 ET1324110.385
10:46 ET186210.395
10:48 ET1206810.37
10:50 ET1334010.385
10:51 ET1795710.385
10:53 ET1062010.375
10:55 ET779710.38
10:57 ET1294410.385
11:00 ET448610.3799
11:02 ET2433510.36
11:04 ET1323210.37
11:06 ET1259110.375
11:08 ET2616610.3835
11:09 ET210010.385
11:11 ET837810.39
11:13 ET756510.39
11:15 ET1177310.39
11:18 ET1525610.395
11:20 ET610710.39
11:22 ET741210.39
11:24 ET2688910.385
11:26 ET724310.3763
11:27 ET965010.385
11:29 ET399910.395
11:31 ET776110.395
11:33 ET2492910.385
11:36 ET880610.39
11:38 ET149110.395
11:40 ET745810.395
11:42 ET192210.4
11:44 ET1011310.405
11:45 ET387510.4095
11:47 ET1383810.42
11:49 ET483610.425
11:51 ET967110.43
11:54 ET226610.435
11:56 ET498910.435
11:58 ET1464710.42
12:00 ET748110.42
12:02 ET1521410.41
12:03 ET30010.41
12:05 ET370210.415
12:07 ET1244410.415
12:09 ET1195510.41
12:12 ET258010.415
12:14 ET1632910.4
12:16 ET383610.4
12:18 ET1348610.4155
12:20 ET474310.415
12:21 ET901710.425
12:23 ET520910.425
12:25 ET708410.425
12:27 ET808610.43
12:30 ET1065710.425
12:32 ET1378510.415
12:34 ET1180310.41
12:36 ET427410.42
12:38 ET1090210.415
12:39 ET710010.41
12:41 ET392310.415
12:43 ET771310.42
12:45 ET180910.415
12:48 ET378710.42
12:50 ET776410.415
12:52 ET288110.415
12:54 ET1304310.435
12:56 ET852910.44
12:57 ET496410.435
12:59 ET334610.44
01:01 ET684310.42
01:03 ET1545210.435
01:06 ET247610.435
01:08 ET1105310.45
01:10 ET641410.44
01:12 ET331910.445
01:14 ET337810.44
01:15 ET1778410.43
01:17 ET73510.43
01:19 ET212510.433
01:21 ET515310.43
01:24 ET1471710.44
01:26 ET1108510.44
01:28 ET50010.44
01:30 ET269210.445
01:32 ET1191510.455
01:33 ET180010.45
01:35 ET267210.45
01:37 ET269710.45
01:39 ET1648010.45
01:42 ET291210.46
01:44 ET1198510.46
01:46 ET103210.46
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesROIV
Roivant Sciences Ltd
7.7B
2.1x
---
United StatesLGND
Ligand Pharmaceuticals Inc
1.5B
15.9x
-12.71%
United StatesCORT
Corcept Therapeutics Inc
3.2B
28.2x
+9.80%
United StatesIMCR
Immunocore Holdings PLC
1.8B
-30.2x
---
United StatesAVDL
Avadel Pharmaceuticals PLC
1.4B
-7.9x
---
United StatesHROW
Harrow Inc
764.4M
-24.2x
---
As of 2024-07-05

Company Information

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor in development across several IgG-mediated autoimmune indications; and brepocitinib, a TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Contact Information

Headquarters
11-12 St. James's Square Suite 1, 3rd FloorLONDON, United Kingdom SW1Y4LB
Phone
207-400-3347
Fax
---

Executives

Independent Chairman of the Board
Ilan Oren
President, Chief Operating Officer
Eric Venker
President, Chief Investment Officer
Mayukh Sukhatme
Chief Executive Officer, Director
Matthew Gline
Chief Financial Officer
Richard Pulik

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.7B
Revenue (TTM)
$124.8M
Shares Outstanding
738.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.24
EPS
$5.07
Book Value
$7.40
P/E Ratio
2.1x
Price/Sales (TTM)
62.0
Price/Cash Flow (TTM)
1.8x
Operating Margin
3,425.45%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.